More severe infectious complications in CLL patients treated with fludarabine, cyclophosphamide, rituximab (FCR) in comparison to bendamustin plus rituximab (BR): Results of the interim-analysis of the CLL10 trial of the German CLL Study Group

被引：0
|
作者：
Langerbeins, P. [1 ]
Busch, R. [2 ]
Schweighofer, C. D. [1 ]
Mueller, C. [1 ]
Fischer, K. [1 ]
Fink, A. -M. [1 ]
Cramer, P. [1 ]
Faetkenheuer, G. [1 ]
Hartmann, P. [1 ]
Stilgenbauer, S. [3 ]
Boettcher, S. [4 ]
Wendtner, C. -M. [5 ]
Hallek, M. [1 ]
Eichhorst, B. [1 ]
机构：
[1] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[2] Tech Univ Munich, Inst Med Stat & Epidemiol, D-80290 Munich, Germany
[3] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany
[4] Univ Hosp Schleswig Holstein, Dept Med 2, Kiel, Germany
[5] Klinikum Schwabing, Dept Internal Med 1, Munich, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V572
引用
收藏
页码：185 / 185
页数：1
相关论文
共 50 条
  • [1] Impact of gender on outcome after chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) or bendamustin plus R (BR) in CLL patients: a pooled analysis of the German CLL Study Group (GCLLSG)
    Al-Sawaf, O.
    Kluth, S.
    Bahlo, J.
    Hopfinger, G.
    Fink, A. M.
    Cramer, P.
    Maurer, C.
    Bergmann, M.
    Dreyling, M.
    Lange, E.
    Kneba, M.
    Stilgenbauer, S.
    Kiehl, M. G.
    Jaeger, U.
    Wendtner, C. M.
    Fischer, K.
    Hallek, M.
    Eichhorst, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 212 - 213
  • [2] Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)
    Fink, Anna
    Busch, Raymonde
    Pflug, Natali
    Boettcher, Sebastian
    Winkler, Dirk
    Buehler, Andreas
    Ritgen, Matthias
    Fischer, Kirsten
    Eichhorst, Barbara
    Wendtner, Clemens-Martin
    Mendila, Myriam
    Wenger, Michael K.
    Doehner, Hartmut
    Kneba, Michael
    Stilgenbauer, Stephan
    Hallek, Michael
    BLOOD, 2011, 118 (21) : 446 - 447
  • [3] Fludarabine, cyclophosphamide and rituximab (FCR) first-line therapy in CLL patients: an analysis of the registry of the German CLL Study Group
    Fink, A. M.
    Federhen, A.
    Kutsch, N.
    Stumpf, J.
    Giza, A.
    Robrecht, S.
    Stoltefuss, A.
    Vehling-Kaiser, U.
    Koenigsmann, M.
    Tausch, E.
    Schneider, C.
    Stilgenbauer, S.
    Illmer, T.
    Schlag, R.
    Doerfel, S.
    Gaska, T.
    Kiehl, M.
    Fischer, K.
    Eichhorst, B.
    Hallek, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 119 - 120
  • [4] SEVERE INFECTIONS ARE MORE COMMON IN PHYSICALLY FIT CLL PATIENTS WITH FCR-THERAPY COMPARED TO BR: RESULTS OF THE INTERMIN-ANALYSIS OF THE CLL10 TRIAL OF THE GERMAN CLL STUDY GROUP
    Langerbeins, P.
    Busch, R.
    Schweighofer, C. D.
    Mueller, C.
    Cramer, P.
    Fink, A. M.
    Faetkenheuer, G.
    Hartmann, P.
    Stilgenbauer, S.
    Boettcher, S.
    Wendtner, C. M.
    Hallek, M.
    Eichhorst, B.
    HAEMATOLOGICA, 2014, 99 : 55 - 56
  • [5] Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)
    Eichhorst, Barbara F.
    Bahlo, Jasmin
    Maurer, Christian
    Lange, Elisabeth
    Koppler, Hubert
    Kiehl, Michael G.
    Sokler, Martin
    Schlag, Rudolf
    Vehling-Kaiser, Ursula
    Kochling, Georg
    Ploger, Christoph
    Gregor, Michael
    Plesner, Torben
    Herling, Marco
    Fischer, Kirsten
    Dohner, Hartmut
    Kneba, Michael
    Wendtner, Clemens
    Klapper, Wolfram
    Kreuzer, Karl-Anton
    Bottcher, Sebastian
    Stilgenbauer, Stephan
    Fink, Anna Maria
    Hallek, Michael
    BLOOD, 2016, 128 (22)
  • [6] Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)
    Eichhorst, Barbara
    Fink, Anna Maria
    Busch, Raymonde
    Kovacs, Gabor
    Maurer, Christian
    Lange, Elisabeth
    Koeppler, Hubert
    Kiehl, Michael G.
    Soekler, Martin
    Schlag, Rudolf
    Vehling-Kaiser, Ursula
    Koechling, Georg R. A.
    Ploeger, Christoph
    Gregor, Michael
    Plesner, Torben
    Trneny, Marek
    Fischer, Kirsten
    Doehner, Hartmut
    Kneba, Michael
    Wendtner, Clemens-Martin
    Klapper, Wolfram
    Kreuzer, Karl Anton
    Stilgenbauer, Stephan
    Boettcher, Sebastian
    Hallek, Michael
    BLOOD, 2014, 124 (21)
  • [7] Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Trial, International, Randomized Study Of The German CLL Study Group (GCLLSG)
    Eichhorst, Barbara
    Fink, Anna-Maria
    Busch, Raymonde
    Lange, Elisabeth
    Koeppler, Hubert
    Kiehl, Michael
    Soekler, Martin
    Schlag, Rudolf
    Vehling-Kaiser, Ursula
    Koechling, Georg
    Ploeger, Christoph
    Gregor, Michael
    Plesner, Torben
    Trneny, Marek
    Fischer, Kirsten
    Doehner, Hartmut
    Kneba, Michael
    Wendtner, Clemens
    Klapper, Wolfram
    Kreuzer, Karl-Anton
    Stilgenbauer, Stephan
    Boettcher, Sebastian
    Hallek, Michael
    BLOOD, 2013, 122 (21)
  • [8] Impact of Gender on Outcome after Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Bendamustine Plus Rituximab (BR) in Patients with Chronic Lymphocytic Leukemia (CLL): A Meta-Analysis of Three Phase II/III Studies of the German CLL Study Group (GCLLSG)
    Al-Sawaf, Othman
    Robrecht, Sandra
    Bahlo, Jasmin
    Fink, Anna Maria
    Cramer, Paula
    Maurer, Christian
    Bergmann, Manuela A.
    Dreyling, Martin H.
    Lange, Elisabeth
    Kneba, Michael
    Stilgenbauer, Stephan
    Dohner, Hartmut
    Kiehl, Michael G.
    Jager, Ulrich
    Wendtner, Clemens-Martin
    Fischer, Kirsten
    Hallek, Michael
    Eichhorst, Barbara F.
    Hopfinger, Georg
    BLOOD, 2016, 128 (22)
  • [9] Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry
    Kutsch, Nadine
    Fink, Anna Maria
    Federhen, Anno
    Giza, Adam
    Robrecht, Sandra
    Stumpf, Janina
    Stoltefuss, Andrea
    Vehling-Kaiser, Ursula
    Koenigsmann, Michael
    Tausch, Eugen
    Schneider, Christof
    Stilgenbauer, Stephan
    Illmer, Thomas
    Schlag, Rudolf
    Doerfel, Steffen
    Gaska, Tobias
    Kiehl, Michael G.
    Fischer, Kirsten
    Eichhorst, Barbara
    Hallek, Michael
    BLOOD, 2022, 140 : 9879 - 9881
  • [10] Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)
    Tam, Constantine S.
    O'Brien, Susan
    Plunkett, William
    Wierda, William
    Ferrajoli, Alessandra
    Wang, Xuemei
    Do, Kim-Anh
    Cortes, Jorge
    Khouri, Issa
    Kantarjian, Hagop
    Lerner, Susan
    Keating, Michael J.
    BLOOD, 2014, 124 (20) : 3059 - 3064
12345